JNJ250110P147000
- 4.62
- +3.37+269.60%
Johnson & Johnson Newsroom
Johnson & Johnson Temporarily Pulls New Treatment for Atrial Fibrillation to Probe Adverse Events
Johnson & Johnson Falls After Pausing Varipulse Cases
8 Health Care Stocks Whale Activity In Today's Session
Express News | J&J - as U.S. External Evaluation Leveraged Unique Platform Configuration, There Is No Impact to Commercial Activity & Varipulse Cases Outside of U.s
Express News | J&J: On Jan 5, Johnson & Johnson Medtech Temporarily Paused U.S. External Evaluation and All U.S. Varipulse Cases
Express News | Johnson & Johnson Statement on Varipulse™ U.S. External Evaluation
Merck, Johnson & Johnson Share Losses Lead Dow's 180-Point Fall
Johnson & Johnson on Track for Lowest Close Since November 2020 -- Data Talk
Johnson & Johnson (JNJ.US) Posdinemab treatment for Alzheimer's disease has received FDA fast track designation.
Pharmaceutical giant Johnson & Johnson (JNJ.US) announced on Wednesday that its proposed drug posdinemab for the treatment of Alzheimer's disease has received Fast Track designation from the USA Food and Drug Administration (FDA). Johnson & Johnson is conducting a Phase 2b study on early Alzheimer’s patients, focusing on an internally discovered tau-targeted monoclonal antibody. The company states that posdinemab has shown potential against the disease-causing phosphorylated tau protein in cerebrospinal fluid of Alzheimer’s patients and has been found to inhibit the development and diffusion of tau protein aggregation in non-clinical models of cognitive impairment.
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
Express News | Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Bernstein Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $177
Express News | Shenzhen Neptunus Bioengineering: The medical instruments Business is less affected by centralized procurement and significant matters of the company are still in progress.
Johnson & Johnson (JNJ) Gets a Hold From Bernstein
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $175
Johnson & Johnson (NYSE:JNJ) Jumps to Year's High on Lung Cancer Drug Success
Johnson & Johnson (JNJ.US) announced positive results from the Phase 3 trial of its dual antibody frontline combination therapy, which can improve the overall survival of cancer patients.
Evaluate the efficacy and safety of the combination of Rybrevant and Lazcluze compared to the active control osimertinib.
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC
Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study